SCHEMBL24252243

SCHEMBL24252243

c1ccc(-c2c3ccccc3c(-c3nc(-c4ccc(-c5cccnc5)cc4)cc(-c4ccc(-c5cccnc5)cc4)n3)c3ccccc23)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.56
CYP19A1 P11511 2/20 0.55
CYP11B1 P15538 2/20 0.47
CYP11B2 P19099 2/20 0.47
CYP17A1 P05093 1/20 0.47
MKNK1 Q9BUB5 3/20 0.46
MKNK2 Q9HBH9 3/20 0.46
ALDH1A1 P00352 6/20 0.46
KDM4E B2RXH2 3/20 0.46
RAB9A P51151 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HSD17B10 Q99714 2/20 0.46
MAPT P10636 2/20 0.46
HPGD P15428 2/20 0.46
NPC1 O15118 1/20 0.46
TP53 P04637 1/20 0.46
CYP1A2 P05177 3/20 0.44
CYP3A4 P08684 3/20 0.44
CYP2A6 P11509 1/20 0.44
GLA P06280 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30857462 1.00 DHODH (0.56) DHODHCYP19A1CYP11B1CYP11B2CYP17A1
SCHEMBL17369027 0.94 DHODH (0.56) DHODHCYP19A1CYP11B1CYP11B2CYP17A1
SCHEMBL22763782 0.94 DHODH (0.56) DHODHCYP19A1CYP11B1CYP11B2CYP17A1
SCHEMBL17918062 0.92 CYP11B2 (0.62) DHODHCYP19A1CYP11B1CYP11B2CYP17A1
SCHEMBL17013859 0.90 DHODH (0.53) DHODHCYP19A1CYP11B1CYP11B2CYP17A1
SCHEMBL24252241 0.90 DHODH (0.53) DHODHCYP19A1CYP11B1CYP11B2CYP17A1
SCHEMBL24252718 0.90 DHODH (0.53) DHODHCYP19A1CYP11B1CYP11B2CYP17A1
SCHEMBL17369026 0.90 DHODH (0.53) DHODHCYP19A1CYP11B1CYP11B2CYP17A1
SCHEMBL24252236 0.90 DHODH (0.53) DHODHCYP19A1CYP11B1CYP11B2CYP17A1
SCHEMBL19486524 0.89 CYP19A1 (0.54) DHODHCYP19A1CYP11B1CYP11B2CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112654611-B Compound having pyrimidine ring structure and organic electroluminescent element 保土谷化学工业株式会社 2024-04-30 CN disclosed
US-20220052268-A1 COMPOUND HAVING PYRIMIDINE RING STRUCTURE AND ORGANIC ELECTROLUMINESCENT ELEMENT HODOGAYA CHEMICAL CO., LTD. (JP) 2022-02-17 US disclosed
CN-112654611-A Compound having pyrimidine ring structure and organic electroluminescent element 保土谷化学工业株式会社 2021-04-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220052268-A1 COMPOUND HAVING PYRIMIDINE RING STRUCTURE AND ORGANIC ELECTROLUMINESCENT ELEMENT SLC29A1, NUDT1, SLC29A2 DHODH 202/4885CYP19A1 2810/4885CYP11B1 4052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.